6 results about "Have Difficulty Swallowing" patented technology

Disclosed is a method for treating dysphagia comprising: fitting a patient afflicted with dysphagia with a TRP oral retainer-based device having an arch for limiting movement of the patient's tongue, the device to be worn by the patient at night starting at about bedtime and during sleep, preferably for at least 8 hours; providing instructions to the patient to wear the device nightly for a period of time from about 2 to about 18 months (the wearing period) as indicated; monitoring the patient's tongue pressure at one or more time points during the wearing period, wherein an increase in tongue strength, as measured for example by tongue pressure (TP) compared to baseline or compared to a prior monitoring time point during the wearing period, indicates that the patient receives a benefit from wearing the device. An increase in tongue strength has been shown to correlate closely with reducing oropharyngeal dysphagia and its attendant symptoms and pathologies.

Provided are an oral dissolving film composition of rivaroxaban, a method for preparing same, and use thereof. The oral dissolving film composition comprises one or more of rivaroxaban and a pharmaceutically acceptable salt, hydrate, and solvate thereof as an active ingredient, and a film-forming material. Also, the present invention features a simple process, no sedimentation during the preparation of film solutions, qualified content uniformity, high drug loading capacity, and improved patient compliance, and is particularly suitable for patients with dysphagia.

This invention provides an orally soluble film composition for rivaroxaban, its preparation method, and its applications. The rivaroxaban orally soluble film composition comprises an active pharmaceutical ingredient and a film-forming material; the active pharmaceutical ingredient is one or more of the following: 5-chloro-nitro-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholino)phenyl]-1,3-azolidin-5-yl}methyl)-2-thiophene-carboxamide, a pharmaceutically acceptable salt, hydrate, and solvate thereof, as shown in Formula I. The rivaroxaban orally soluble film composition provided by this invention has the advantages of good taste, stable properties, high dissolution, and immediate dissolution in the oral cavity without the need for drinking water, without a gritty feeling after dissolution in the oral cavity, and rapid oral absorption. Furthermore, the process of this invention is simple, no sedimentation occurs during the preparation of the film solution, the content uniformity meets requirements, the drug loading is high, and clinical patient compliance is improved, making it particularly suitable for patients with swallowing difficulties, and it has good market prospects.

This invention provides a cariprazine orally disintegrating film composition, its preparation method, and its application. The orally disintegrating film composition comprises an active ingredient, a film-forming material, and a plasticizer, wherein the active ingredient is selected from one or more mixtures of cariprazine, pharmaceutically acceptable salts of cariprazine, and their inclusion compounds. The orally disintegrating film composition of this invention has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without water, and rapid oral absorption. It also features a simple process, high drug loading capacity, and good drug content uniformity. The orally disintegrating film composition of this invention helps improve medication compliance, medication retention, and vomiting in patients with schizophrenia, and is particularly suitable for patients with swallowing difficulties, showing promising market prospects.

The present invention discloses novel innovative compositions containing concentrated mucus extracted from okra, as well as methods of making these compositions. At least a portion of the composition may be used in a ready to drink (RTD) beverage or as a powder, and may be used to treat an individual with dysphagia. One example method includes at least one step selected from the group consisting of: precooking fresh or frozen whole okra pods; cutting the okra into slices; immersing the okra slices in water; separating an okra mucus concentrate from the okra tablets by filtration; adding an excipient material; the mixture containing the okra mucus concentrated solution is homogenized; subjecting the mixture to heat treatment or sterilization; and adjusting the okra mucus concentration in the heat-treated or sterilized mixture to achieve a relaxation time at 20 DEG C of at least 10 milliseconds, preferably 50 milliseconds to 400 milliseconds and most preferably 100 milliseconds to 200 milliseconds.

The application provides a cariprazine orally dissolving film composition, a preparation method and application thereof. The orally dissolving film composition comprises an active ingredient, a film forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and an inclusion compound thereof. The orally dissolving film composition has the advantages of thin thickness, good taste, stable property, instant dissolving in the oral cavity without drinking water, fast oral absorption speed, simple process, high drug loading, good drug content uniformity, and the like. The orally dissolving film composition helps to improve the poor compliance, hiding and spitting of patients with schizophrenia, and is particularly suitable for patients with difficulty in swallowing, and has a good market prospect.